21 June 2021 - Deborah Wilkes
Mark Keatley – former chief financial officer of Stada – has joined the boards of Sweden’s Karo Pharma, Germany’s Neuraxpharm and Sweden’s Recipharm.
All three companies are controlled by private-equity firms. EQT controls Karo and Recipharm, while Permira owns Neuraxpharm.
Keatley was one of the advisers to private-equity firms Bain Capital and Cinven during their EUR5.3 billion (USD6.3 billion) acquisition of Stada in 2017. Stada said he “played a leading role in initiating and implementing the transformation of the company to improve efficiency and productivity”.
Stada announced in February 2020 that Keatley was stepping down as chief financial officer after two and a half years in the post (click here to read the News story).
He was chief financial officer of Actavis Group until its sale in 2012.